BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33049255)

  • 1. Targeting the population for gene therapy with MYBPC3.
    Carrier L
    J Mol Cell Cardiol; 2021 Jan; 150():101-108. PubMed ID: 33049255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
    Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
    J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.
    Barefield D; Kumar M; de Tombe PP; Sadayappan S
    Am J Physiol Heart Circ Physiol; 2014 Mar; 306(6):H807-15. PubMed ID: 24464755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
    Viswanathan SK; Sanders HK; McNamara JW; Jagadeesan A; Jahangir A; Tajik AJ; Sadayappan S
    PLoS One; 2017; 12(11):e0187948. PubMed ID: 29121657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy.
    Mori AA; Castro LR; Bortolin RH; Bastos GM; Oliveira VF; Ferreira GM; Hirata TDC; Fajardo CM; Sampaio MF; Moreira DAR; Pachón-Mateos JC; Correia EB; Sousa AGMR; Brión M; Carracedo A; Hirata RDC; Hirata MH
    Forensic Sci Int Genet; 2021 May; 52():102478. PubMed ID: 33588347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene.
    Cardim N; Perrot A; Santos S; Morgado P; Pádua M; Ferreira S; Reis RP; Monteiro C; Ferreira T; Correia JM; Osterziel KJ
    Rev Port Cardiol; 2005 Dec; 24(12):1463-76. PubMed ID: 16566405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology.
    Carrier L; Mearini G; Stathopoulou K; Cuello F
    Gene; 2015 Dec; 573(2):188-97. PubMed ID: 26358504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.
    Sedaghat-Hamedani F; Kayvanpour E; Tugrul OF; Lai A; Amr A; Haas J; Proctor T; Ehlermann P; Jensen K; Katus HA; Meder B
    Clin Res Cardiol; 2018 Jan; 107(1):30-41. PubMed ID: 28840316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
    Van Driest SL; Vasile VC; Ommen SR; Will ML; Tajik AJ; Gersh BJ; Ackerman MJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1903-10. PubMed ID: 15519027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
    Calore C; De Bortoli M; Romualdi C; Lorenzon A; Angelini A; Basso C; Thiene G; Iliceto S; Rampazzo A; Melacini P
    J Med Genet; 2015 May; 52(5):338-47. PubMed ID: 25740977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial and Functional Distribution of
    Helms AS; Thompson AD; Glazier AA; Hafeez N; Kabani S; Rodriguez J; Yob JM; Woolcock H; Mazzarotto F; Lakdawala NK; Wittekind SG; Pereira AC; Jacoby DL; Colan SD; Ashley EA; Saberi S; Ware JS; Ingles J; Semsarian C; Michels M; Olivotto I; Ho CY; Day SM
    Circ Genom Precis Med; 2020 Oct; 13(5):396-405. PubMed ID: 32841044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertrophic cardiomyopathy-linked variants of cardiac myosin-binding protein C3 display altered molecular properties and actin interaction.
    Da'as SI; Fakhro K; Thanassoulas A; Krishnamoorthy N; Saleh A; Calver BL; Safieh-Garabedian B; Toft E; Nounesis G; Lai FA; Nomikos M
    Biochem J; 2018 Dec; 475(24):3933-3948. PubMed ID: 30446606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of Autophagy Ameliorates Cardiomyopathy in
    Singh SR; Zech ATL; Geertz B; Reischmann-Düsener S; Osinska H; Prondzynski M; Krämer E; Meng Q; Redwood C; van der Velden J; Robbins J; Schlossarek S; Carrier L
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29021349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene.
    Lekanne Deprez RH; Muurling-Vlietman JJ; Hruda J; Baars MJ; Wijnaendts LC; Stolte-Dijkstra I; Alders M; van Hagen JM
    J Med Genet; 2006 Oct; 43(10):829-32. PubMed ID: 16679492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic diagnosis of hypertrophic cardiomyopathy using mass spectrometry DNA arrays and high resolution melting.
    Santos S; Lança V; Oliveira H; Branco P; Silveira L; Marques V; Brito D; Madeira H; Bicho M; Fernandes AR
    Rev Port Cardiol; 2011 Jan; 30(1):7-18. PubMed ID: 21425739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The R820W mutation in the MYBPC3 gene, associated with hypertrophic cardiomyopathy in cats, causes hypertrophic cardiomyopathy and left ventricular non-compaction in humans.
    Ripoll Vera T; Monserrat Iglesias L; Hermida Prieto M; Ortiz M; Rodriguez Garcia I; Govea Callizo N; Gómez Navarro C; Rosell Andreo J; Gámez Martínez JM; Pons Lladó G; Cremer Luengos D; Torres Marqués J
    Int J Cardiol; 2010 Nov; 145(2):405-407. PubMed ID: 20542340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of heterozygous and homozygous mouse models with the most common hypertrophic cardiomyopathy mutation MYBPC3
    Hilderink S; Schuldt M; Goebel M; Jansen VJ; Manders E; Moorman S; Dorsch LM; van Steenbeek FG; van der Velden J; Kuster DWD
    J Mol Cell Cardiol; 2023 Dec; 185():65-76. PubMed ID: 37844837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myosin-binding Protein C Compound Heterozygous Variant Effect on the Phenotypic Expression of Hypertrophic Cardiomyopathy.
    Rafael JF; Cruz FEDS; Carvalho ACC; Gottlieb I; Cazelli JG; Siciliano AP; Dias GM
    Arq Bras Cardiol; 2017 Apr; 108(4):354-360. PubMed ID: 28538763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
    Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
    J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy.
    Helms AS; Davis FM; Coleman D; Bartolone SN; Glazier AA; Pagani F; Yob JM; Sadayappan S; Pedersen E; Lyons R; Westfall MV; Jones R; Russell MW; Day SM
    Circ Cardiovasc Genet; 2014 Aug; 7(4):434-43. PubMed ID: 25031304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.